Despite guidelines that advocate watching and waiting, physicians are still treating most patients with immune thrombocytopenia.
Collaboration and innovative thinking result in a new technology platform to improve the patient experience.
Profiling reveals histologic subtype distinctions and heterogeneity of neurofibromatosis type 1-associated tumors.
Recent study results suggest that combining virotherapy and PD-1 blockades may be more effective than either approach alone.
In some ways, the group appears more resilient than survivors of adult-onset cancer or those with other childhood-onset diseases.
The phase 1 trial shows safety and tolerance of HSV1716 in the pediatric population; evidence of viral replication in the blood and acute inflammation on PET/CT scans suggest a phase 2 trial for dosage and efficacy is warranted.
The synergistic effects of a kinase inhibitor and an oncolytic herpes virus show promise for difficult-to-treat neuroblastomas and malignant peripheral nerve sheath tumors.
